ATTENTION: Please enable Javascript in your browser for full site functionality.
Skip to navigation Skip to main content Skip to footer

Updates

SUB-TYPE: CLASS 3 RECALL

Class 3 recall-GoResp Digihaler

Teva UK Limited has informed the MHRA that it plans to withdraw from further sale all batches of GoResp Digihaler (budesonide and formoterol fumarate dihydrate) and the linked Digihaler App for commercial reasons.

MHRA Drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-teva-uk-limited-goresp-digihaler-el-24-a-slash-23?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=9edb0dde-bbc2-4ee4-8039-9d803a602c9c&utm_content=immediately

 

Pip code

Product description

Supplier

Batch Numbers

4250197

GORESP DIGIHALER 160/4.5MCG GB

TEVA UK LTD

ALL

4250080

GORESP DIGIHALER 320/9MCG (GB)

TEVA UK LTD

ALL

 

 

 

Further Information

For medical information, please contact medinfo@tevauk.com (Tel. 02075 407117) and stock control enquiries please contact customer.services@tevauk.com (Tel. 0800 590502).

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

 

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in use- Oxcarbazepine Mylan 150 mg, 300mg, 600mg Film-Coated Tablets

Viatris UK Healthcare Limited has informed the MHRA that the Patient Information Leaflet (PIL) packaged in the specified batches of Oxcarbazepine 150 mg, 300 mg & 600 mg Film-Coated Tablets do not contain the most up to date safety information.

 

MHRA Drug alert date: 17th June 2024

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-viatris-uk-healthcare-ltd-oxcarbazepine-mylan-150-mg-300mg-600mg-film-coated-tablets-el-24-a-slash-22

 

Pip code

Product description

Supplier

Batch Numbers

1135763

OXCARBAZEPINE TAB 150MG MYL

VIATRIS

A4659   A4660

1135755

OXCARBAZEPINE TAB 300MG MYL

VIATRIS

N3560   A4705

1135748

OXCARBAZEPINE TAB 600MG MYL

VIATRIS

M3556

 

 

This is a caution in use only we are not accepting stock returns

 

Further Information

For medical information and stock control queries please contact:

Viatris UK Healthcare Limited Medical Information at +44 (0)1707 853 000 (select option 1) or info.uk@viatris.com. Customer Services can be reached at +44 (0)1707 853 000 (select option 2).

SUB-TYPE:

AstraZeneca products available to order from Alliance Healthcare from 1 July 2024

 

Alliance Healthcare is pleased to announce a new reduced wholesale agreement with AstraZeneca, effective from 1 July 2024.


Nisha Vibhakar, Head of Supply Chain, AstraZeneca UK said: "This new model has allowed us to review all our current processes and strengthen controls. I look forward to working with our new partners.”


Marie Evans, Managing Director, Alliance Healthcare UK adds: “Our agreement with AstraZeneca gives all UK pharmacies fast and reliable access to this range of products, through Alliance Healthcare’s unique, twice daily delivery service." 


UK Healthcare Professionals can find out more details at AstraZeneca’s UK Supply Chain Website: https://www.supplychain-astrazeneca.co.uk/


Our Account Managers are ready to answer any questions about ordering.

 

AZ
 

SUB-TYPE: FIELD SAFETY NOTICE

Field Safety notice-Tegaderm - Transparent Film Dressing Frame Style

We have received a recall notice from 3M regarding two batches of Tegaderm Transparent film dressings

 

Date of recall: 31/05/24

 

Pip code

Product description

Supplier

Batch Numbers

2428951

TEGADERM 1632P-10 DRSG 12CMSQ

3M

104841330  106615553

 

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

 

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

 

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 caution in use-Paracetamol 500mg, 1000mg Film-Coated Tablets Drugs R Us

Dawa Limited has informed the MHRA that specified batches listed in this notification have been packed with an outdated Patient Information Leaflet (PIL).

 

MHRA Drug alert date: 10th June 2024

MHRA drug alert link  https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-dawa-limited-paracetamol-500mg-1000mg-film-coated-tablets-el-24-a-slash-21

 

Pip code

Product description

Supplier

Batch Numbers

8055493

PARACETAMOL FC TAB 1000MG

DRUGS R US LTD (GENERICS)

220106

6835102

PARACET TAB (CAPL) 500MG ALM

DRUGS R US LTD (GENERICS)

220103  220105

 

 

 

This is a caution in use only we are not accepting stock returns

 

Further Information

For more information, medical information and stock control queries please contact Drugsrus Limited (distributor) on 020 8423 3800 or email info@drugsrus.co.uk.

SUB-TYPE:

Leanne Carey, of Barnton Pharmacy in Edinburgh, discusses her thoughts on Pharmacy First in a piece for P3 Magazine

 

Adapting to a new paradigm: Learnings from Pharmacy First Scotland

Contractors in England are experiencing their first year of delivering Pharmacy First, but a similar service has been running in Scotland since 2020. Scottish pharmacist Leanne Carey describes the experience as wholly positive.

 

The Pharmacy First scheme was launched in England this year to give patients quick and accessible care and to ease pressure on GP services for a number of conditions that pharmacists encounter and identify on a daily basis.

 

For my pharmacy in Scotland, Pharmacy First was introduced in July 2020, allowing pharmacists to prescribe OTC items from a specific formulary. This was extended by adding Patient Group Directions (UTI in women, impetigo, shingles, cellulitis and infected bites and allergies,) and then Pharmacy First Plus, using independent prescriber (IP) skills for common conditions in January 2021.

Although the Pharmacy First schemes in England and Scotland differ slightly, there are a number of lessons we have learned which will be applicable to pharmacies across England.

 

bn

 

Rolling out Pharmacy First effectively

Firstly, the great benefit of the Pharmacy First scheme is that it elevates the role of pharmacists and staff, allowing us to have more influence in treating patients.

 

Under the scheme, patients can visit their local pharmacy without needing to book an appointment with their GP for certain minor ailments.

 

In England, full payment is received by referral from the GP. Pharmacists, equipped with their expertise and knowledge, can offer advice, treatment, and refer patients to other healthcare providers. The scheme also leads to greater job satisfaction; it is much more rewarding to be able to treat a patient than having to refer them to a GP.

 

Trust and confidence

After the roll-out of Pharmacy First in my pharmacy, we found that the scheme enhanced the patient and customer relationship.

 

By offering healthcare services beyond dispensing, our staff had the opportunity to build stronger relationships with patients. This has created trust and confidence in our staff’s expertise, which has led to higher patient satisfaction and loyalty.

 

Our prescription items and retail sales have increased by around 8 per cent each year since the service was established, despite giving more advice than prescriptions.

 

Patients choose to come to us first for advice, again and again.

 

We are part of the Alphega Pharmacy group, which was helpful for us in launching the service and getting the most out of it, including providing consultation forms that help staff get the information they need from patients to offer advice or make a referral.

 

Addressing capacity concerns

Pharmacies across England already have incredibly skilled and capable staff. However, it is understandable that some pharmacies have concerns about capacity.

 

Pharmacy staff are trained to triage patients, support with advice and OTC medication, and refer to pharmacists or technicians. We also involve pharmacy students training in branch, so they are able to support with checking patient symptoms. This training frees up the time of pharmacists and prescribers and is an excellent learning opportunity for all colleagues.

 

I have two post-foundation pharmacists at the moment (one full time and one part time) who stayed on after their foundation year training to be supported with the IP course and develop clinical skills to assess patients under supervision, gaining confidence in the process. This has meant I have continued to have capacity to assess patients and prescribe, support other IPs through the Teach and Treat hub I run as well as managing the business.

 

Making access to care more equitable for all

The Pharmacy First scheme is a significant step forward in transforming the role of community pharmacists and improving healthcare accessibility for patients across England, with more than 95 per cent of pharmacies already signed up. By capitalising on pharmacists’ expertise, the scheme not only benefits patients but allows pharmacists to have a greater role in patient care within their communities.

 

The Pharmacy First scheme empowers pharmacists to play a more integral role in delivering primary healthcare services. As this initiative continues to evolve, it will no doubt drive positive outcomes for both patients and pharmacists alike, creating healthier outcomes for all.

 

 

Leanne Carey is an independent prescribing community pharmacist who has owned and run Alphega member Barnton Pharmacy in Edinburgh for more than 14 years.

 

Published online at: Adapting to a new paradigm: Learnings from Pharmacy First Scotland (p3pharmacy.co.uk)

SUB-TYPE: CLASS 3 RECALL

Class 3 recall-Atomoxetine 10mg, 18mg, 25mg, 40mg Capsules

Neuraxpharm UK Ltd is recalling specific batches after retesting showed out of specification results. The tabled batches are being recalled as a precautionary measure after testing showed variability of the capsule contents beyond permitted levels.

 

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-neuraxpharm-uk-ltd-atomoxetine-10mg-18mg-25mg-40mg-capsules-el-24-a-slash-19

 

Pip code

Product description

Supplier

Batch Numbers

8009334

ATOMOXETINE CAP 10MG

NEURAXPHARM UK LTD

1211145  1203816

8009342

ATOMOXETINE CAP 18MG

NEURAXPHARM UK LTD

1211146

8009375

ATOMOXETINE CAP 25MG

NEURAXPHARM UK LTD

1211147  1207940

8009383

ATOMOXETINE CAP 40MG

NEURAXPHARM UK LTD

1211148  1203818

 

 

Further Information

 

For medical information enquiries please contact medinfo-uk@neuraxpharm.com or telephone +44 (0) 118 211 4039

 

For stock control enquiries please contact info-uk@neuraxpharm.com  or telephone +44 (0) 118 211 4039

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

SUB-TYPE: CLASS 2 RECALL

Class 2 recall-Lamotrigine Desitin oral suspension

Desitin Pharma UK Ltd is recalling all batches of Lamotrigine Desitin 10mg/ml Oral Suspension as a precautionary measure due to an out of specification observation in the appearance of samples during routine stability testing. Please note this is a Class 2 Patient, Pharmacy and Wholesaler level recall.

 

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-desitin-pharma-uk-ltd-lamotrigine-desitin-10mg-slash-ml-oral-suspension-el-24-a-slash-20?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=9f3210f7-f22d-4437-be34-72c69edae87e&utm_content=immediately

 

Pip code

Product description

Supplier

Batch Numbers

1272780

LAMOTRIGINE DESITIN 10MG/ML OS

DESITIN PHARMA LTD

SEE ABOVE LINK

 

 

Further Information

For medical information enquiries please contact medinfo@desitin.co.uk. For stock control enquiries please contact alison.wilton@desitin.co.uk.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 caution in use-Betamethasone Ointment 0.1% 30g

Manx Healthcare Ltd. has informed MHRA that they have identified a problem with the product packaging of the batch indicated

 

MHRA Drug alert date: 3rd June 2024

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-manx-healthcare-ltd-dot-betamethasone-valerate-0-dot-1-percent-ointment-el-24-a-slash-18?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=f6354607-981b-4e64-96f4-50ae75da2efb&utm_content=immediately

 

Pip code

Product description

Supplier

Batch Numbers

8085151

BETAMETHASONE OINT 0.1% W/W

MANX  HEALTHCARE

G0039

 

 

This is a caution in use only we are not accepting stock returns

 

Further Information

For medical information enquiries please contact medinfo@manxhealthcare.com, or telephone: +44 (0)1926 482511.

 

For stock control enquiries please contact customerservice@manxhealthcare.com, or telephone: +44 (0)1926 482511.

SUB-TYPE:

Alliance Healthcare UK to enter into a new reduced wholesale agreement with AstraZeneca: July 2024

 

We are pleased to announce that, as of 1 July 2024, Alliance Healthcare UK will become one of the chosen wholesalers to supply selected products of AstraZeneca’s product portfolio to all pharmacies, hospital pharmacies, and doctors in the United Kingdom, including Northern Ireland.

 

Click here for full product details.